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SUMMARY 
Background: Cardiovascular disease is the major cause of hospitalization and mortality in chronic kidney disease 
(CKD). C-reactive protein (CRP) is a marker of cardiovascular disease and predictor of mortality in CKD patients. 
CKD patients with elevated CRP should be identified early with institution of measures to treat cardiovascular risk 
factors in order to reduce attendant mortality.  
Aims: Determination of serum CRP levels in CKD patients and associated factors. 
Methods: This was a case-control study involving 80 consecutive CKD patients and 40 control subjects without 
CKD. Data obtained from participants included demographics, body mass index (BMI), and aetiology of CKD. Se-
rum CRP levels, albumin, creatinine and lipid profile were determined. Cases and controls were compared. P values 
<0.05 were taken as significant 
Results: The mean age of the CKD subjects was 49.09±16.85 years. The median CRP value was significantly higher 
in the CKD group compared to controls (p=<0.001). Low, average and high cardiovascular event risk according to 
CRP values were present in 51(63.8%), 13(16.2%) and 16(20%) of the CKD patients respectively. Cardiovascular 
event risk was significantly higher in CKD subjects (p=<0.001). Serum creatinine, BMI, triglyceride and atherogen-
ic index of plasma correlated positively with CRP. Estimated glomerular filtration rate (eGFR), high density lipopro-
tein-cholesterol and albumin correlated negatively with CRP. Elevated serum CRP was significantly predicted by 
low eGFR and high BMI on multivariate analysis. 
Conclusion: Chronic kidney disease patients have increased cardiovascular event risk. Interventions aimed at reduc-
ing weight and treating dyslipidaemia should be instituted early in order to reduce this risk. 
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INTRODUCTION 
Cardiovascular disease (CVD) accounts for about 40% 
of hospitalization and 50% of mortality in CKD patients 
at all stages.1,2  In end stage renal disease (ESRD) pa-
tients, CVD mortality rate is about 10-20 times higher 
than  the general population.3 The process of CVD most 
likely started in early stages of CKD considering  its 
severity at commencement of renal replacement therapy 
(RRT).4  
 
Elevated serum C-reactive protein (CRP) levels have 
been shown to be linked with the development of ather-
osclerosis in CKD patients.5 C-reactive protein is an 
acute phase reactant that belongs to the protein family 
known as pentraxin.  
It is synthesized by the liver in response to cytokines 
such as interleukin-1, interleukin-6, tumour necrosis 
factor-alpha released from macrophages and adipocytes.  
 
Chronic kidney disease is a chronic inflammatory state 
caused by both patient and dialysis related factors. The-
se factors include the uremic milieu, infection, oxidative 
stress, co-morbidities, obesity, genetic or immunologic 
factors, exposure to dialyzer membrane and dialysate in 
those on dialysis.6  
 
The levels of inflammatory markers like fibrinogen, 
homocysteine, CRP are high in CKD patients with cor-
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Consequences of chronic inflammation in CKD patients 
include malnutrition, anaemia, hypo-responsiveness to 
erythropoietin, CVD and increased mortality.8-10 
 
Amuk et al reported that CRP and endothelial function 
could provide complementary prognostic information 
regarding future cardiovascular disorders in renal pa-
tients.11   Earlier   reports   have also established   CRP 
as a valuable predictor of future cardiovascular events in 
CKD. 12,13 
 
C-reactive protein levels of <1 mg/L, 1 to 3 mg/L, and 
>3 mg/L correspond to low, moderate, and high-risk 
groups for future cardiovascular events.14 Therefore, 
CKD patients with a high cardiovascular event risk can 
be closely monitored and aggressive cardiovascular risk 
factor modification instituted before they develop cardi-
ovascular disease.  
 
The aim of this study was to determine serum levels of 
CRP and its relationship with other parameters in CKD 




The Renal Unit, Department of Internal Medicine of 
University of Benin Teaching Hospital receives referral 
from within and outside the state of location.  An aver-
age of 12 newly diagnosed CKD patients are seen in the 
unit monthly while about same number commence 
maintenance haemodialysis monthly. 
 
Study Design 
This was a case control study spanning one year period 
(September 2012 to August 2013) that involved 80 con-
secutive pre-dialysis CKD patients and 40 age matched 
controls with normal renal function.  Sample size was 
derived using the Fleiss formula15 for case-control study  
with  the following information:  
 
Confidence interval = 95%, power of study = 80%, ratio 
of cases to control of 2:1, percentage of control ex-
posed: 28 16 and percentage of cases exposed: 62.17 This 
formula gave a minimum sample size of 50 for cases 
and 25 for control.  
 
Inclusion criteria for CKD subjects were: adults aged ≥ 
18 years, patients with CKD stages 1-5 yet to com-
mence dialysis and those who gave consent to partici-
pate in the study. CKD patients with positive HIV, hep-
atitis B or hepatitis C status, those with chronic liver 
disease, those with active infection and those on statins 
or who smoke were excluded from the study. Inclusion 
criteria for control subjects were adults aged ≥18 years 
with normal renal function, absence of chronic liver 
disease, negative hepatitis B, hepatitis C and HIV status, 
not being on lipid lowering medications and who do not 
smoke.  
 
Questionnaires were administered to the study subjects 
by the researchers to obtain demographic information 
such as age, gender and clinical history such as history 
of renal symptoms, common aetiologies such as hyper-
tension, diabetes mellitus, retroviral disease, haemoglo-
binopathy, obstructive uropathy, connective tissue dis-
ease and previous or family history of renal disease. 
Study subjects were physically examined and their 
blood pressure measurements were taken. Blood pres-
sure of subjects was measured in sitting position after 5 
minutes rest, on the right arm using a mercury sphyg-
momanometer. The systolic and diastolic pressures were 
read to the nearest 2 mmHg. Systolic BP and diastolic 
BP were taken at phase 1 and phase 5 Korotkoff sounds 
respectively. The average of 3 consecutive BP readings 
taken at 5 minutes interval was recorded. Weight was 
measured using a weighing scale made by U-MEC 
(model 98114) with subjects wearing light clothing. 
Height was measured  using a stadiometer to the nearest 
centimeter with subjects neither wearing shoes nor head 
gear. Body mass index (kg/m2) was calculated using the 
formula; Weight (kg) / Height 2 (m) 2.  
 
The aetiology of renal disease in CKD subjects were 
determined by the researchers using the information 
obtained from administered questionnaires, physical 
examination findings and investigations in patients’ 
clinical folders as follow: 
Diabetic nephropathy: A diagnosis of diabetes mellitus, 
features of other microvascular complications, presence 
of hypertension, significant proteinuria, presence of 
large or normal sized kidneys on ultrasound in the ab-
sence of other possible aetiological factors. 
 
Hypertensive nephropathy: a history of long standing 
hypertension, presence of features of long standing hy-
pertension such as hypertensive retinopathy, thickened 
arterial wall, locomotor brachialis, loud aortic compo-
nent of second heart sound. 
 
Sickle cell nephropathy: sickle cell disease patient with 
or without nephrotic range proteinuria, normal sized or 
enlarged kidneys on ultrasound, absence of other aetio-
logical factors like DM and hypertension. 
 
Autosomal dominant polycystic kidney disease: pres-
ence of ≥ 3 cysts, which may be unilateral or bilateral in 
patients aged between 15-39 years, ≥ 2 cysts in each 
kidney for patients aged 40-59 and ≥ 4 cysts in each 
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Chronic glomerulonephritis: past history of acute glo-
merulonephritis or nephrotic syndrome, active urinary 
sediments, significant proteinuria, bilaterally shrunken 
kidneys absent features of long standing hypertension, 
DM or other aetiological factors. 
 
Obstructive uropathy: presence clinical features of uri-
nary obstruction, dilated pelvi-calyceal system, normal 
or enlarged kidneys on ultrasound in the absence of oth-
er aetiological factors.  
 
About 10mls of fasting venous blood was obtained from 
patients to perform tests, which included PCV, serum 
CRP, albumin, creatinine and fasting serum lipids. 
Glomerular filtration rate (GFR) was estimated using 
the MDRD formula, which has been previously validat-
ed in Nigerian subjects.18 
 
C-Reactive Protein Assay 
Serum C-reactive protein was analyzed by enzyme-
linked immunosorbent assay (ELISA) technique. High 
sensitivity-CRP ELISA method is based on the principle 
of solid phase ELISA  in which the CRP in the sample 
is sandwiched between immobilised monoclonal anti-
bodies and anti-CRP antibodies in the enzyme conjugate 
solution. The washing off of the unbound labelled anti-
bodies and reaction with tetramethylbenzidine (TMB) 
reagent lead to the development  of  colour, which in-
tensity is proportional to the concentration of CRP in 
the sample. 
Ten microliters of appropriately diluted CRP standard, 
samples and controls were dispensed into appropriately 
labeled microtitre wells (that have been brought to room 
temperature i.e (20-250C) after which 100µl of enzyme 
conjugate reagent was added, thoroughly mixed for 30 
seconds and incubated at 20-25 0C for 45 minutes. The 
wells were later washed for 5 times with distilled water 
and properly dried by striking sharply on absorbent pa-
per. 100µl of tetremethylbenzidine solution was then 
added to each well, gently mixed for 5 seconds and in-
cubated at 20-250C for 20 minutes. Thereafter, 100µl of 
1N hydrochloric acid (stop solution) was added to each 
well, gently mixed for 30 seconds to stop the reaction 
and for the development of a yellow colour, the absorb-
ance which was read with a microtitre well reader at 450 
nm within 15 minutes. The concentration of CRP in 
milligram per decilitre (mg/dl) was calculated thus: 
CRP (mg/dl)  =  As    X  Cstd 
                      Astd 
Where; As is the absorbance for the samples or controls, 
Astd is the absorbance for the standard and Cstd is the 
concentration for the standard.  
The assay was done in duplicates and the mean CRP 
calculated for each sample and control. 
 
Definition of terms  
Chronic Kidney disease has been defined as the pres-
ence of markers of kidney damage for more than  3 
months with or without reduction in GFR or as the pres-
ence of GFR less than or equal to 60ml/min/1.73m2 for 
3 months with or without other signs of kidney dam-
age.19   
 
CKD stage 1 (GFR ≥ 90 mls/min with evidence of kid-
ney damage), stage 2 (GFR 60-89 mls/min  with evi-
dence of kidney damage), stage 3 (GFR = 30-59 
mls/min with or without evidence of kidney damage), 
stage 4 (GFR =15-29 mls/ min with or without evidence 
of kidney damage) and stage 5 (GFR < 15mls/min with 
or without evidence of kidney damage).19 Atherogenic 
index of plasma (AIP) was derived using  log(TG/HDL-
C).20  
 
Serum CRP levels < 1mg/dl, 1-3mg/dl and > 3mg/dl 
were used to stratify the study subjects into  low cardio-
vascular event  risk, average cardiovascular event risk 
and high cardiovascular event  risk respectively.14 
 
Data Protection 
Data were stored using Microsoft Excel program, kept 
secured and only released for analysis when needed. 
Confidentiality was maintained and the anonymity of 
responses ensured. Personal identifiers were not collect-
ed from participants 
 
Data Analysis 
Data generated were analysed using the statistical pack-
age for social sciences (SPSS) version 17.0. Results 
were presented in tabular form. Univariate analysis was 
used in description of demographic characteristics of the 
study population. Continuous variables were presented 
as means and standard deviation for unskewed data and 
median, interquartile range for skewed data. Student t-
test was used to compare mean values of the CKD and 
control subjects for those with unskewed data while 
Mann Whitney U was used to compare skewed data. 
Discrete variables were presented as frequency and per-
centages. Chi-square test was used to determine the sig-
nificant associations between categorical variable. 
Spearman’s correlation was used to determine associa-
tion between serum CRP and other variables while  
Multiple linear regression was used to determine the 
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Ethical approval was obtained from the hospital ethical 
committee on research and informed consent was ob-
tained from participants. 
 
RESULTS 
This study involved 80 CKD patients and 40 control 
subjects without CKD. The CKD group comprised of 53 
males and 27 females.  Majority of the CKD subjects 
were 65 years and below, accounting for 69(86.3%) of 
the CKD patients.  
 
Diabetes mellitus, chronic glomerulonephritis and hy-
pertension were the major aetiology of renal disease, 
accounting for 30(37.5%), 24(30%) and 23(28.8%) re-
spectively.  
 
Forty (50%) of the CKD patients were in CKD stage 4 
or 5.  Fifty-one (63.8%) of the CKD subjects had serum 
CRP values of < 1mg/L, 13(16.2%) had   value of be-
tween 1-3mg/L while the remaining 16(20%) had values 
>3mg/L (Table 1) 
 
Table 1 Characteristics of Study subjects (CKD patients 
and Control subjects) 
Parameter CKD group 
n (%) 





   
Male 53 (66.3) 25(62.5) 0.84 
Female 27 (33.7) 15(37.5)  
Age    
  ≤65years 69 (86.3) 35(87.5) 0.92 
  >65 years  11 (13.7) 5(12.5)  
Diagnosis    
Chronic glomerulonephritis 24 (30.0)   
Hypertensive nephropathy 23 (28.8)   




  2 (2.5) 
   1(1.2) 
  
CKD stages    
1 5 (6.2)   
2 9 (11.2)   
3 26 (32.5)   
4 30 (37.5)   
5 10(12.5)   
Serum CRP values    
<1mg/L 51(63.8) 38(95)  
1-3mg/L 13(16.2) 2(5) <0.001 
>3mg/L 16(20.0) 0(0)  
SCN (Sickle cell nephropathy), ADPKD (Autosomal dominant poly-
cystic kidney disease),CRP (c-reactive protein) 
 
There was no significant difference in the mean age, 
BMI, total cholesterol and LDL-C between the CKD 
and control groups. The mean systolic BP, diastolic BP, 
serum creatinine was significantly higher in the CKD 
group with p values of <0.001. The median value of 
serum TG, CRP and AIP were significantly higher in 
the CKD group with p values of <0.001.   
 
Table 2 Comparison of parameters between CKD and 
Control groups 







Age (years) 49.09±16.85 45.28±15.20 0.215 
Body mass 
index (kg/m2) 
24.77±4.50 26.08±4.00 0.15 
Systolic BP 
(mmHg) 
160.77±28.84 128.60±16.94 <0.001* 
Diastolic BP 
(mmHg) 
94.93±20.49 81.02±10.50 <0.001* 
Serum Creati-
nine (mg/dl) 
3.04±1.60 0.90±0.22 <0.001* 
eGFR† 
(mls/min) 
30.19(27.7) 104.89(38.22) <0.001* 
Serum Albumin 
(mg/l) 
41.40±7.29 45.41±6.96 0.005* 
Serum CRP† 
(mg/dl) 
0.54(2.17) 0.1(0.24) <0.001* 
PCV (%) 25.81±7.37 39.16±6.12 <0.001* 
Serum TC 
(mg/l) 
173.96±47.63 179.87±42.19 0.494 
Serum TG† 
(mg/l) 
103(60) 62.50(55) <0.001* 
Serum LDL-C † 
(mg/l) 
93(43) 89.65(70) 0.166 
Serum HDL-C 
(mg/l) 
51.08±17.60 78.82±27.88 <0.001* 
AIP† 0.34(0.31) -0.13(0.58) <0.001* 
*(Significant p value<0.05)†Skewed data expressed in Median (IQR) 
and Mann Whitney U test used. Sd(Standard deviation) IQR (Inter-
quartile range),  eGFR (estimated glomerular filtration rate). HDL-C 
(High density lipoprotein- cholesterol), TG (Triglyceride), TC (Total 
cholesterol), LDL-C (low density lipoprotein cholesterol) PCV 
(packed cell volume), BP (blood pressure), AIP (atherogenic index of 
plasma), CRP (C-reactive protein)          
 
The mean serum albumin and PCV were significantly 
lower in the CKD group with p-values of   0.005 and 
<0.001 respectively. The median values of serum HDL-
C and estimated GFR were significantly lower in the 
CKD group with p values of <0.001(Table 2). 
 
 
C-reactive protein levels had significant positive corre-
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0.01, r = 0.28), serum creatinine (p = 0.02, r = 0.26) and 
AIP (p = 0.01, r = 0.30). There were also significant 
negative correlation between CRP and serum albumin 
(p= 0.001,r = -0.36), HDL-C (p = 0.02, r = -0.26) and 
estimated GFR(p = 0.01,r = 0.30) (Table 3). 
 
Table 3 Linear Correlation between CRP level and oth-




Age (years) 0.78 0.03 
Body mass index (Kg/m2) 0.004
* 
0.34 
Serum Creatinine (mg/dl) 0.02* 0.26 
Serum Albumin (mg/l) 0.001
* 
-0.36 
Packed cell volume (%) 0.58 -0.06 
Serum TC (mg/dl) 0.60 -0.06 
Serum TG (mg/dl) 0.01* 0.28 
Serum HDL-C (mg/dl) 0.02* -0.26 
Serum LDL-C (mg/dl) 0.46 -0.08 
Estimated GFR (ml/min/1.73m2) 0.01* -0.28 
AIP 0.01* 0.30 
*(Significant p value<0.05)  
Glomerular filtration rate (GFR). HDL-C (High density lipoprotein- 
cholesterol), TG (Triglyceride), TC (Total cholesterol), LDL-C (low 
density lipoprotein cholesterol) PCV (packed cell volume), BP (blood 
pressure), AIP (atherogenic index of plasma), CRP (C-reactive pro-
tein) , BMI(body mass index) 
 
On multiple linear regression analysis, the significant 
predictors of elevated serum CRP in the CKD patients 
were low eGFR (p = 0.03) and high BMI (p = 0.03) 
(Table 4). 
 
Table 4 Multiple regression analysis to determine pre-






t P-value B Std. Error Beta 
1 (Constant) 0.77 2.07  0.37 0.71 
TG 0.01 0.02 0.20 0.42 0.68 
HDL-C -0.04 0.04 -0.29 -0.91 0.36 
BMI 0.12 0.05 0.26 2.22 0.03 
AIP -1.79 5.16 -0.23 -0.35 0.73 
eGFR -0.02 0.01 -0.26 -2.18 0.03 
eGFR (Estimated Glomerular filtration rate), HDL-C (High density 
lipoprotein- cholesterol), TG (Triglyceride), T, AIP (atherogenic index 






According to the serum CRP values, 29 (36.2%) of the 
CKD subjects had moderate to high cardiovascular 
event risk compared to only 2(5%) of the control sub-
jects who had moderate cardiovascular event risk.  
This showed that cardiovascular event risk is signifi-
cantly higher in CKD subjects. 
 
Majority of the CKD patients in this study were below 
65 years of age and the common aetiologies of CKD 
were diabetes mellitus, chronic glomerulonephritis and  
hypertension  which  was similar to  previous reports 
from Nigeria.21,22  Also, about 50%  of these patients 
had stage 4 or 5 CKD which  may be due to late presen-
tation and  poor health seeking attitude of Nigerians.23 
 
C-reactive protein has been reported to be highly valua-
ble in predicting cardiovascular risk in CKD patients.11-
13  Its level correlates with carotid intima media thick-
ness in  CKD patients, hence can serve as a biomarker 
to estimate cardiovascular risk.24  C-reactive protein has 
also been implicated as an actual promoter of athero-
sclerotic disease progression by binding to LDL, facili-
tating its deposition on the arterial wall and activating 
the complement system.25,26 
 
The median serum level of hsCRP was significantly 
higher in the CKD group compared to the controls who 
did not have CKD. This suggests that the process of 
inflammation in CKD starts before  dialysis and it is not 
entirely dialysis related since the CKD subjects in this 
study were dialysis naive. There was significant positive 
correlation between CRP and serum creatinine on one 
hand and negative correlation with estimated GFR on 
the other hand. Estimated GFR was also found to be a 
significant predictor of CRP levels in CKD in this study. 
This study showed that inflammation as measured by 
CRP level increases with declining renal function in 
CKD patients, similar to previous reports.11,13,27  Inter-
ventions aimed at reducing cardiovascular event risk 
should therefore be started as soon as a diagnosis of 
CKD is made irrespective of the stage. 
 
C-reactive protein correlated negatively with serum 
albumin, a finding similar to previous studies.28,29  C-
reactive protein and serum albumin are markers of in-
flammation and independent risk factors for all-cause 
mortality in CKD patients.10 Serum albumin may there-
fore serve as an alternative to CRP in assessing cardio-
vascular event risk in CKD patients in resource poor 




There was significant positive correlation between CRP 
and BMI in this study. Body mass index was the second 
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agrees with previous reports in both CKD and non-CKD 
subjects.27,30-32  
 
Visceral fat secretes pro-inflammatory cytokines that 
attracts macrophages that infiltrate adipocytes leading to 
further release of cytokines and oxygen free radicals 
which ultimately cause oxidative damage and athero-
sclerosis.33-35  
 
Carvalho et al in a prospective study, reported a rela-
tionship between serum CRP levels and changes in BMI 
and waist circumference in pre-dialysis CKD subjects.36 
Weight loss was reported to reduce CRP level in both 
CKD and non-CKD subjects.32,36 This suggests  that 
measures aimed at weight reduction in CKD may reduce 
CRP level with subsequent reduction in cardiovascular 
event risk.  
 
There was also significant association between some 
lipid parameters and CRP level in this study. Serum 
CRP correlated positively with serum TG and AIP and 
negatively with serum HDL-C. The AIP has been re-
ported to have higher sensitivity compared to other lipid 
ratios in estimating atherogenic index and predicting 
cardiovascular events in both CKD and non-CKD pa-
tients.20,37,38  These associations therefore, buttress the 
fact that CRP is associated with increased cardiovascu-
lar event risk in CKD patients. Similar association be-
tween CRP and HDL-C has been reported in  both  pre-
dialysis CKD and end stage renal disease subjects who 
were on maintenance dialysis.39,40   
 
This study also found an association between CRP and 
HDL-C. This  finding is particularly important because 
high density lipoprotein cholesterol has both antioxidant 
and anti-inflammatory effects, 41   hence patients with 
low HDL-C may have higher degree of inflammation 
and oxidative stress.  
 
Therapeutic interventions and lifestyle modification 
aimed at treating dyslipidaemia will be valuable in re-
ducing the level of CRP. Statins, angiotensin converting 
enzyme inhibitors and angiotensin receptor blockers 
have anti-inflammatory properties and may have addi-
tional benefits apart from their direct effects on lipids, 
blood pressure and proteinuria in reducing CVD mor-
bidity and CKD progression.42,43 Some studies have also 
shown that statins can reduce the levels of CRP in sub-
jects with and without CKD.42,44 
 
The limitations of this study  were  the relatively small 
sample size and the ratio of cases to control was 2:1 due 
to limitation of funds because this study was self-
sponsored.  
 
Also, it was a single centre study and may not be a re-
flection of what pertains to other centres in Nigeria. 
However, this is the first study in Nigeria to determine 
serum CRP levels and its associated factors in predialy-
sis CKD patients. 
 
Recommendation: Therapeutic intervention and lifestyle 
modification aimed at reducing weight and treating 
dyslipidaemia should be instituted early in CKD pa-
tients in order to reduce associated cardiovascular risk 
and progression to ESRD  
 
CONCLUSION 
CKD patients have increased CRP values. Body mass 
index, HDL-C, TG, AIP, and eGFR are factors related 
to CRP levels in CKD patients. 
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